Negative / Null Result ReportMedicine
Sehgal K, Serritella A, Liu M et al. · 2025 · The Journal of clinical endocrinology and metabolism
Background There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC) and radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) refractory to multikinase inhibitors. This…
View details →DOI: 10.1210/clinem/dgae443 Negative / Null Result ReportMedicine
Yazici Y, Tambiah JRS, Swearingen CJ et al. · 2025 · Clinical and experimental rheumatology
Objectives To determine the efficacy, safety, and tolerability of intraarticular (IA) lorecivivint (LOR) in the treatment of knee osteoarthritis (OA). Methods Patients with American College of Rheumatology criteria-defined knee OA,…
View details →DOI: 10.55563/clinexprheumatol/hjt118 Negative / Null Result ReportMedicine
Gratzke C, Özgüroğlu M, Peer A et al. · 2025 · Annals of oncology : official journal of the European Society for Medical Oncology
Background Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III…
View details →DOI: 10.1016/j.annonc.2025.05.008 Negative / Null Result ReportMedicine
Guckenberger M, Opitz I, Dellaporta T et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Objective To evaluate the addition of immunotherapy and metastasis-directed stereotactic body radiotherapy (SBRT) to induction chemotherapy followed by definitive local therapy of the locoregional primary tumour in patients with…
View details →DOI: 10.1016/j.lungcan.2025.108553 Negative / Null Result ReportMedicine
Lee JB, Choi SJ, Shim HS et al. · 2025 · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Introduction Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB to IIIA NSCLC harboring EGFR mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated…
View details →DOI: 10.1016/j.jtho.2024.12.023 Negative / Null Result ReportOpen accessMedicine
Wills CA, Mohan S, Nabavizadeh A et al. · 2025 · Neuro-oncology advances
Background Novel treatments are needed for oligodendroglioma that has recurred following radiotherapy (RT) and chemotherapy. The cyclin D1-CDK4 axis is frequently dysregulated in oligodendroglioma. Abemaciclib is a selective CDK4/6…
View details →DOI: 10.1093/noajnl/vdaf011 Negative / Null Result ReportOpen accessMedicine
Cheng S, Kordbacheh T, Banyard A et al. · 2026 · Oncology research
Objectives The PACIFIC trial established the benefit of durvalumab following chemo-radiotherapy for stage III non-small cell lung cancer (NSCLC). However, the concurrent use of radiotherapy (RT) and durvalumab (PACIFIC-2 trial) showed no…
View details →DOI: 10.32604/or.2025.072053 Negative / Null Result ReportMedicine
Kaufman MR, Goldman HB, Chermansky CJ et al. · 2024 · Neurourology and urodynamics
Aims This study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI). Methods Adult females were randomized 2:1 to iltamiocel (150 × 10 6…
View details →DOI: 10.1002/nau.25588 Failed Experiment ReportOpen accessMedicine
Cree BAC, Freedman MS, Gold M et al. · 2025 · Annals of neurology
Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in…
View details →DOI: 10.1002/ana.27262 Failed Experiment ReportMedicine
Lee JM, Miller A, Rose PG et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose We assessed the efficacy of anti-PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior…
View details →DOI: 10.1158/1078-0432.ccr-24-3877 Negative / Null Result ReportMedicine
Gong J, Mita AC, Wei Z et al. · 2024 · JCO precision oncology
Purpose Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies.…
View details →DOI: 10.1200/po.23.00406 Negative / Null Result ReportOpen accessMedicine
King B, Mesinkovska N, Senna M et al. · 2025 · Journal of the European Academy of Dermatology and Venereology : JEADV
Background Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).…
View details →DOI: 10.1111/jdv.20605 Negative / Null Result ReportMedicine
Schulte B, Mohindra N, Milhem M et al. · 2021 · British journal of cancer
Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with…
View details →DOI: 10.1038/s41416-021-01448-0 Negative / Null Result ReportOpen accessMedicine
Thavaneswaran S, Lin F, Espinoza D et al. · 2025 · NPJ precision oncology
This single-arm phase II trial (ACTRN12620000918921) evaluated the clinical activity of tremelimumab (10 mg/kg intravenously every 4 weeks for 6 cycles) in advanced cancers with a high tumour mutational burden (TMB), defined as TMB > 10…
View details →DOI: 10.1038/s41698-025-01156-5 Negative / Null Result ReportOpen accessMedicine
Hsu YC, Lin PT, Teng W et al. · 2024 · Cancers
Background The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for…
View details →DOI: 10.3390/cancers16203458 Negative / Null Result ReportMedicine
Harada H, Omori S, Mori K et al. · 2022 · International journal of clinical oncology
Background This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Methods The major inclusion criteria were…
View details →DOI: 10.1007/s10147-022-02151-7 Failed Experiment ReportMedicine
Andres S, Finch L, Iasonos A et al. · 2024 · Gynecologic oncology
Objective To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT),…
View details →DOI: 10.1016/j.ygyno.2024.06.026 Replication FailureOpen accessMedicine
Takagi K, Saito G, Tanaka H et al. · 2025 · ESMO open
Background The REMORA trial demonstrated efficacy and safety of lenvatinib in patients previously treated for advanced thymic carcinoma. However, more data regarding its use in clinical practice are required. Methods This multicenter…
View details →DOI: 10.1016/j.esmoop.2025.105301 Negative / Null Result ReportMedicine
Kerwin E, Dorinsky P, Patel M et al. · 2022 · The Journal of asthma : official journal of the Association for the Care of Asthma
Objective To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β 2 -agonists (ICS/LABA) with or…
View details →DOI: 10.1080/02770903.2021.1938603 Negative / Null Result ReportOpen accessMedicine
Kirschner P, Konen FF, Axhausen F et al. · 2026 · Therapeutic advances in neurological disorders
Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or…
View details →DOI: 10.1177/17562864261427169 Negative / Null Result ReportMedicine
Lumish M, Chui MH, Zhou Q et al. · 2024 · Gynecologic oncology
Objective HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but…
View details →DOI: 10.1016/j.ygyno.2023.12.028 Negative / Null Result ReportOpen accessMedicine
Cecchini M, Kwiek B, Liu-Walsh F et al. · 2026 · Dermatology and therapy
Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-agonizing/depleting…
View details →DOI: 10.1007/s13555-026-01746-6 Negative / Null Result ReportOpen accessMedicine
Chang JY, Balch C, Oh HS · 2024 · Viruses
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or…
View details →DOI: 10.3390/v16091476 Negative / Null Result ReportMedicine
Sabha M, Siaton BC, Hochberg MC · 2020 · Expert opinion on investigational drugs
Introduction : Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health-related quality of life, and increased mortality. To date, all…
View details →DOI: 10.1080/13543784.2020.1842357 Replication FailureOpen accessMedicine
Nagpal S, Nguyen KS, Bertrand S et al. · 2025 · Cancer reports (Hoboken, N.J.)
Background Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective.…
View details →DOI: 10.1002/cnr2.70330 Negative / Null Result ReportOpen accessMedicine
Lin CL, Chen MC, Lin CY et al. · 2026 · Journal of robotic surgery
Minimally invasive total mesorectal excision (TME) for rectal cancer can be performed via transanal TME (TaTME) or robotic TME (R-TME), yet comparative evidence in predominantly non-obese Asian cohorts remains limited. We evaluated a…
View details →DOI: 10.1007/s11701-026-03241-8 Negative / Null Result ReportOpen accessMedicine
Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…
View details →DOI: 10.1038/s41392-025-02173-3 Negative / Null Result ReportOpen accessMedicine
Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…
View details →DOI: 10.1136/jitc-2023-008409 Negative / Null Result ReportOpen accessMedicine
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
View details →DOI: 10.3390/cancers18111802 Negative / Null Result ReportMedicine
Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
View details →DOI: 10.1007/s40261-020-00905-7 